Research programme: small molecule therapeutics - Interprotein

Drug Profile

Research programme: small molecule therapeutics - Interprotein

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Interprotein Corporation
  • Class Small molecules
  • Mechanism of Action CD antigen inhibitors; Interleukin receptor antagonists; Protein-protein interaction inhibitors; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Research Cancer; Inflammation

Most Recent Events

  • 31 Oct 2017 Research programme: small molecule therapeutics - Interprotein is available for licensing as of 31 Oct 2017. http://www.interprotein.com/program.html
  • 31 Oct 2017 Early research in Cancer in Japan (unspecified route)
  • 31 Oct 2017 Early research in Inflammation in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top